Yuan W.,General Hospital of Chengdu Military District |
Yuan W.,Ohio University |
Yuan Y.,Ohio University |
Zhang T.,General Hospital of Chengdu Military District |
Wu S.,Ohio University
PLoS ONE | Year: 2015
Radiotherapy is a widely used treatment for cancer. However, recent studies suggest that ionizing radiation (IR) can promote tumor invasion and metastasis. Bmi-1, a member of the polycomb group protein family, has been observed as a regulator of oxidative stress and promotes metastasis in some tumors. But, its potential role in the metastasis induced by IR of breast cancer has not been explored. In our study, we found that increased levels of Bmi-1 were correlated to EMT of breast cancer cells. Through analyzing the EMT state and metastasis of breast cancer induced by IR, we found the metastatic potential of breast cancer cells can either be inhibited or accelerated by IR following a time-dependent pattern. Silencing Bmi-1 completely abolished the ability of the IR to alter, reduce or increase, the migration of breast cancer cells. Also, when Bmi-1 was knocked down, the effect of inhibition of PI3K/AKT signaling on EMT affected by IR was blocked. These results suggest that Bmi-1 is a key gene in regulation of EMT and migration of breast cancer cells induced by IR through activation of PI3K/AKT signaling; therefore, Bmi-1 could be a new target for inhibiting metastasis caused by IR. © 2015 Yuan et al.
Zhang X.,General Hospital of Chengdu Military District |
Liu H.,General Hospital of Chengdu Military District
Cancer Research and Clinic | Year: 2014
Uterine carcinosarcomas are highly aggressive and rare tumours composed of epithelial and mesenchymal elements. Although hysterectomy with bilateral salpingooophorectomy remains the main treatment, high rates of recurrence and metastases need for lymphadenectomy and postoperative adjuvant treatment. Though radiation improves locoregional control, the role of it in improving overall survival outcomes remains undecided. Although various combinations of chemotherapy have been explored, an optimal therapeutic modality is to be determined. Overall survival rates have not improved in thirty years. Targeted chemotherapy and a multimodality approach may be better outcomes.
Peng J.-J.,General Hospital of Chengdu Military District |
Wei D.,General Hospital of Chengdu Military District |
Li D.,General Hospital of Chengdu Military District |
Fu Z.-Q.,General Hospital of Chengdu Military District |
And 4 more authors.
PLoS ONE | Year: 2013
Background:Peptidylprolyl cis/trans isomerase NIMA-interacting 1 (PIN1) is involved in the process of tumorigenesis. The two single nucleotide polymorphisms (-677T>C, -842G>C) in the PIN1 promoter region have been suspected of being associated with cancer risk for years, but the conclusion is still inconclusive.Methods:Eligible case-control studies were retrieved by searching databases and references of related reviews and studies. Genotype distribution data, adjusted odds ratios (ORs) and 95% confidence (CIs) intervals were extracted to calculate pooled ORs.Results:A total of 4619 cancer cases and 4661 controls were included in this meta-analysis. Overall, the PIN1 -667T>C polymorphism was not associated with cancer risk, while the -842C allele was significantly associated with reduced cancer risk (CC+GC vs. GG, OR = 0.725, 95% CI: 0.607-0.865; Pheterogeneity = 0.012 and GC vs. GG: OR = 0.721, 95% CI: 0.591-0.880; Pheterogeneity = 0.003). Results from genotype distribution data were in agreement with those calculated with adjusted ORs and 95% CIs. No publication bias was detected.Conclusions:Results of this meta-analysis suggest that the PIN1 -842G>C polymorphism is associated with decreased cancer risk, but that the -667T>C polymorphism is not. © 2013 Peng et al.